Fabrice André
A5001814176- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Estrogen and related hormone effects
- RNA modifications and cancer
- Fibroblast Growth Factor Research
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Gene expression and cancer classification
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Cancer Diagnosis and Treatment
Institut Gustave Roussy
2016-2025
Université Paris-Saclay
2016-2025
Inserm
2016-2025
Protéomique, Réponse Inflammatoire et Spectrométrie de Masse
2020-2024
Université Paris-Sud
2015-2024
Prédicteurs moléculaires et nouvelles cibles en oncologie
2020-2024
Proteogenomics Research Institute for Systems Medicine
2021-2024
Predict (France)
2021-2023
The University of Texas MD Anderson Cancer Center
2005-2023
Council of Science Editors
2022-2023
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Purpose Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherapy survival between patients with TNBC non-TNBC. Patients Methods Analysis a prospectively collected clinical database was performed. We included 1,118 who received at M.D. Anderson Cancer Center for stage I-III from 1985 2004 whom complete information were...
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity early studies.
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit chemotherapy.We used immunohistochemical analysis to determine expression excision repair cross-complementation group 1 (ERCC1) protein in operative specimens cancer. The had been enrolled International Lung Cancer Trial, thereby allowing a comparison effect adjuvant on survival, according ERCC1...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) negative human epidermal growth factor 2 (HER2).In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy safety selective CDK4/6 inhibitor ribociclib combined with letrozole first-line treatment 668 postmenopausal women HR-positive, HER2-negative recurrent metastatic who had...
The AACR Project GENIE is an international data-sharing consortium focused on generating evidence base for precision cancer medicine by integrating clinical-grade genomic data with clinical outcome tens of thousands patients treated at multiple institutions worldwide. In conjunction the first public release from approximately 19,000 samples, we describe goals, structure, and standards report conclusions high-level analysis initial phase data. We also provide examples utility data, such as...
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. In phase 1 dose-finding study, majority the patients with advanced HER2-positive breast cancer had response to trastuzumab (median duration, 20.7 months). The efficacy in metastatic previously treated emtansine requires confirmation.In this two-part, open-label, single-group,...
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 CDK6), which promote progression from the G1 phase to S cell cycle. We assessed efficacy palbociclib (an inhibitor CDK4 CDK6) fulvestrant in advanced cancer.This 3 study involved 521 patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative that had relapsed or progressed during prior endocrine therapy. randomly assigned a 2:1 ratio receive placebo...
BACKGROUND: DC derived-exosomes are nanomeric vesicles harboring functional MHC/peptide complexes capable of promoting T cell immune responses and tumor rejection. Here we report the feasability safety first Phase I clinical trial using autologous exosomes pulsed with MAGE 3 peptides for immunization stage III/IV melanoma patients. Secondary endpoints were monitoring outcome. PATIENTS AND METHODS: Exosomes purified from day 7 monocyte derived-DC cultures. Fifteen patients fullfilling...
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed...
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...